内科理论与实践

内科理论与实践 >

2023 , Vol. 18 >Issue 02: 128 - 130

DOI: https://doi.org/10.16138/j.1673-6087.2023.02.014

综述

生长分化因子15：减重治疗的新靶点

展开
  • 1.盐城市中医院老年科，江苏 盐城 224000
    2.南京中医药大学附属中西医结合医院内分泌科 江苏省中医药研究院，江苏 南京 210028

收稿日期: 2021-08-09

  网络出版日期: 2023-05-15

基金资助

国家自然科学基金项目(81800756);江苏省第十六批“六大人才高峰”高层次人才选拔培养项目(WSN-035)

收起

Growth differentiation factor 15: a new target for weight management

Expand

Received date: 2021-08-09

  Online published: 2023-05-15

Fold

本文引用格式

张梦潇, 韦晓, 张少红, 陈国芳, 刘超 . 生长分化因子15：减重治疗的新靶点[J]. 内科理论与实践, 2023 , 18(02) : 128 -130 . DOI: 10.16138/j.1673-6087.2023.02.014

参考文献

[1] Francque S, Szabo G, Abdelmalek MF, et al. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(1): 24-39.
[2] Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial[J]. Lancet, 2018, 391(10120): 541-551.
[3] Baek SJ, Okazaki R, Lee SH, et al. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia[J]. Gastroenterology, 2006, 131(5): 1553-1560.
[4] Xiong Y, Walker K, Min X, et al. Long-acting MIC-1/GDF15 molecules to treat obesity: evidence from mice to monkeys[J]. Sci Transl Med, 2017, 9(412).
[5] Baek SJ, Eling T. Growth differentiation factor 15 (GDF15)[J]. Pharmacol Ther, 2019, 198: 46-58.
[6] Hsu JY, Crawley S, Chen M, et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15[J]. Nature, 2017, 550(7675): 255-259.
[7] Tsai VWW, Husaini Y, Sainsbury A, et al. The MIC-1/GDF15-GFRAL pathway in energy homeostasis[J]. Cell Metab, 2018, 28(3): 353-368.
[8] Wiklund FE, Bennet AM, Magnusson PK, et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15)[J]. Aging Cell, 2010, 9(6): 1057-1064.
[9] Ahmed DS, Isnard S, Lin J, et al. GDF15/GFRAL pathway as a metabolic signature for cachexia in patients with cancer[J]. J Cancer, 2021, 12(4): 1125-1132.
[10] Yang L, Chang CC, Sun Z, et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand[J]. Nat Med, 2017, 23(10): 1158-1166.
[11] Mullican SE, Lin-Schmidt X, Chin CN, et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates[J]. Nat Med, 2017, 23(10): 1150-1157.
[12] Emmerson PJ, Wang F, Du Y, et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL[J]. Nat Med, 2017, 23(10): 1215-1219.
[13] Tsai VW, Macia L, Johnen H, et al. TGF-b superfamily cytokine MIC-1/GDF15 is a physiological appetite and body weight regulator[J]. PLoS One, 2013, 8(2): e55174.
[14] Chung HK, Ryu D, Kim KS, et al. Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis[J]. J Cell Biol, 2017, 216(1): 149-165.
[15] Chrysovergis K, Wang X, Kosak J, et al. NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism[J]. Int J Obes(Lond), 2014, 38(12): 1555-1564.
[16] Frikke-Schmidt H, Hultman K, Galaske JW, et al. GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice[J]. Mol Metab, 2019, 21: 13-21.
[17] Dolo PR, Yao L, Liu PP, et al. Effect of sleeve gastrectomy on plasma growth differentiation factor-15 (GDF15) in human[J]. Am J Surg, 2020, 220(3):725-730.
[18] Kleinert M, Bojsen-M?ller KN, J?rgensen NB, et al. Effect of bariatric surgery on plasma GDF15 in humans[J]. Am J Physiol Endocrinol Metab, 2019, 316(4): E615-E621.
[19] Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin[J]. Diabetologia, 2017, 60(9): 1577-1585.
[20] Gerstein HC, Pare G, Hess S, et al. Growth differentiation factor 15 as a novel biomarker for metformin[J]. Diabetes Care, 2017, 40(2): 280-283.
[21] Coll AP, Chen M, Taskar P, et al. GDF15 mediates the effects of metformin on body weight and energy balance[J]. Nature, 2020, 578(7795): 444-448.
[22] Zhao J, Li M, Chen Y, et al. Elevated serum growth differentiation factor 15 levels in hyperthyroid patients[J]. Front Endocrinol (Lausanne), 2019, 9: 793.
[23] Breit SN, Brown DA, Tsai VW. The GDF15-GFRAL pathway in health and metabolic disease[J]. Annu Rev Physiol, 2021, 83: 127-151.
[24] Tsai VW, Zhang HP, Manandhar R, et al. GDF15 mediates adiposity resistance through actions on GFRAL neurons in the hindbrain AP/NTS[J]. Int J Obes (Lond), 2019, 43(12): 2370-2380.
[25] Johnen H, Lin S, Kuffner T, et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1[J]. Nat Med, 2007, 13(11): 1333-1340.
[26] Hale C, Véniant MM. Growth differentiation factor 15 as a potential therapeutic for treating obesity[J]. Mol Metab, 2021, 46: 101117.
[27] Patel S, Alvarez-Guaita A, Melvin A, et al. GDF15 provides an endocrine signal of nutritional stress in mice and humans[J]. Cell Metab, 2019, 29(3): 707-718.
[28] Campderrós L, Moure R, Cairó M, et al. Brown adipocytes secrete GDF15 in response to thermogenic activation[J]. Obesity, 2019, 27(10): 1606-1616.
[29] Lee SE, Kang SG, Choi MJ, et al. Growth differentiation factor 15 mediates systemic glucose regulatory action of T-helper type 2 cytokines[J]. Diabetes, 2017, 66(11): 2774-2788.
[30] Eddy AC, Trask AJ. Growth differentiation factor-15 and its role in diabetes and cardiovascular disease[J]. Cytokine Growth Factor Rev, 2021, 57: 11-18.
Options
文章导航

/

〈 〉